Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it intended to invite any such offer or invitation.

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "**US Securities Act**"), and may not be offered or sold in the United States unless registered under the US Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the US Securities Act. The Company has no intention to register under the US Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*

XDC

WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

COMPLETION OF CONNECTED TRANSACTION INVOLVING SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE

Financial Adviser

J.P.Morgan

CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE

Reference is made to the announcement (the "**Announcement**") and the circular ("**Circular**") of WuXi XDC Cayman Inc. (the "**Company**") dated September 3, 2025 and September 22, 2025, respectively, in relation to the Subscription. Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the Announcement and the Circular.

The Board is pleased to announce that the completion of the Subscription took place on October 22, 2025 in accordance with the terms and conditions of the Subscription Agreement, where an aggregate of 24,134,000 new Shares were successfully subscribed by WuXi Biologics, at the Subscription Price of HK$58.85 per Subscription Share.

The net proceeds from the Subscription (after deducting all fees, costs and expenses incurred by the Company in connection with the Subscription) is approximately HK$1,414.47 million (equivalent to approximately US$181.25 million), and the net price per Subscription Share is approximately HK$58.61. For further details on the use of proceeds, please refer to the Circular.

EFFECT OF SHAREHOLDING STRUCTURE OF THE COMPANY FOLLOWING COMPLETION OF THE SUBSCRIPTION

The shareholding structure of the Company (a) immediately before completion of the Subscription; and (b) immediately after completion of the Subscription are set out below:

Name of Shareholder	**Immediately before completion of the Subscription**		**Immediately after completion of the Subscription**	
	No. of Shares	*Approximate percentage of the issued share capital of the Company*	*No. of Shares*	*Approximate percentage of the issued share capital of the Company*
WuXi Biologics	611,350,500	49.75%	635,484,500	50.72%
STA Pharmaceutical Hong Kong Investment Limited	232,900,000	18.95%	232,900,000	18.59%
Dr. Zhisheng Chen	418,878	0.03%	418,878	0.03%
Other Public Shareholders	384,058,239	31.26%	384,058,239	30.65%
Total	1,228,727,617	100%	1,252,861,617	100%

Note:

(1) The percentages of the shareholding in the table above may not add up to 100% due to rounding.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincai LI
Executive Director and Chief Executive Officer

Hong Kong, October 22, 2025

For the purpose of this announcement, conversion of US$ into HK$ is based on the exchange rate of US$1.00 to HK$7.8038. The exchange rate is used for illustration purposes only and should not be taken as a representation that the HK$ amount could actually be converted into US$ at that rate, or at all.

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincai LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

* *For identification purpose only*